Disease-modifying effects of glucocorticoids in rheumatoid arthritis;Krankheitsmodifizierende effekte bei der rheumatoiden arthritis durch glukokortikoide

Zeitschrift fur Rheumatologie

Volumn 66, Issue 6, 2007, Pages 522-524

  Buttgereit, F ^a   Burmester, G ^a   Bijlsma, J W ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

DMARDs; Glucocorticoids; Long term outcome; Radiographic progression; Rheumatoid arthritis

Indexed keywords

GLUCOCORTICOID;

ARTICLE; DRUG EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; RADIOGRAPHY; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; LONG-TERM CARE; PAIN MEASUREMENT;

EID: 35748980553     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-007-0185-1     Document Type: Article

References (12)

1. Buttgereit F, Straub RH, Wehling M, Burmester GR (2004) Glucocorticoids in the treatment of rheumatic diseases. An update on mechanisms of action. Arthritis Rheum 50: 3408-3417
2. Bijlsma JWJ, Hoes JN, van Everdingen AA (2006) Are Glucocorticoids DMARDs? Ann N Y Acad Sci 1069: 268-274
3. Bijlsma JWF, Buttgereit F, Jacobs JWG (2006) Systemic and intra-articular glucocorticoids in rheumatoid arthritis. In: Firestein GS, Panayi GS, Wollheim FA (eds) Rheumatoid Arthritis. Oxford University Press, pp 337-354
4. Buttgereit F, Saag K, Cutolo M et al. (2005) The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheum 34:14-21
5. Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136: 1-12
6. Jacobs JW, van Everdingen AA, Verstappen SMM, Bijlsma JW (2006) Follow-up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 54: 1422-1428
7. Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333: 142-146
8. Boers M, Verhoeven AC, Markusse HM et al. (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309-318
9. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double blind placebo-controlled trial. Arthritis Rheum 52: 3371-3380
10. Svensson B, Boonen A, Albertsson K et al. (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52: 3360-3370
11. Capell HA, Madhok R, Hunter JA et al. (2004) Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 63: 797-803
12. Kirwan J, Bijlsma JWJ, Boers M, Shea B (2007) Effects of glucocorticoids on radiological progession in rheumatoid arthritis. Cochrane Databas Syst Rev Jan 24;1:CD006356